CinCor Pharma, Inc.
CINC · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18 | $17 | $10 | $11 |
| G&A Expenses | $5 | $4 | $4 | $14 |
| SG&A Expenses | $5 | $4 | $4 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $21 | $14 | $25 |
| Operating Income | -$22 | -$21 | -$14 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $0 | -$3 | -$4 |
| Pre-Tax Income | -$21 | -$21 | -$17 | -$29 |
| Tax Expense | -$1 | -$1 | $3 | $4 |
| Net Income | -$20 | -$21 | -$20 | -$33 |
| % Margin | – | – | – | – |
| EPS | -0.48 | -0.54 | -0.59 | -0.94 |
| % Growth | 11.1% | 8.5% | 37.2% | – |
| EPS Diluted | -0.48 | -0.54 | -0.59 | -0.94 |
| Weighted Avg Shares Out | 41 | 38 | 33 | 35 |
| Weighted Avg Shares Out Dil | 41 | 38 | 33 | 35 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $3 | -$4 |
| EBITDA | -$20 | -$21 | -$14 | -$29 |
| % Margin | – | – | – | – |